Thyrocare Technologies Limited
Quality (93/100) does the heavy lifting; valuation (16/100) is the drag.
ExpensiveOvervaluedThyrocare Technologies Limited earns a Hold from StocksWizard, with a blended score of 45/100. At ₹566.85 it trades above our blended DCF and relative-multiples fair value of ₹315.15, about 44% downside to that estimate — we read it as overvalued by 44%. On 51.2x trailing earnings it sits pricier than the Healthcare median of about 37.4x. The price is about 13% below its 52-week high of ₹649.35 and 64% above the low of ₹345.06. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 8/9. The average analyst target of ₹603 implies about 6% upside across 5 analysts. It clears 11 of 14 investability checks, with durability 93, valuation 32 and momentum 57 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹252.12.
Analyst views
1-year price
EOD · 2026-09-2552-week range
-12.71% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 8/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 28.7%
- Pass: Low debt (D/E < 0.5): 0.09x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 20%
- Pass: Earnings growing: 116%
- Pass: Net margin ≥ 10%: 19.7%
- Pass: Current ratio > 1.5: 3.39
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Fail: Above 50-day average
- Pass: Positive 1-year return
- Pass: Altman Z in safe zone: Z 35.21
- Pass: Piotroski ≥ 7: 8/9
Quarterly results
Annual financials
Shareholding
- Promoter61.1%
- Institutions21.5%
- Public & other17.4%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Strong return on equity (28.7%).
- Lightly leveraged balance sheet.
- Healthy profit margin (19.7%).
- Up 44% over the past year.
- Financially solid — Altman Z 35.21.
- High Piotroski quality score (8/9).
Opportunities
- Earnings growing (116% YoY).
- Revenue growing (20% YoY).
Bear case
Threats
- Trades ~44% above our estimated fair value.
About Thyrocare Technologies Limited
Thyrocare Technologies Limited operates diagnostic testing services across India through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment sells consumables for specimen collection and promotes pathology services to patients, laboratories, and hospitals.
Thyrocare Technologies Limited — frequently asked questions
Is Thyrocare Technologies Limited a buy, hold or sell?
StocksWizard currently rates Thyrocare Technologies Limited (THYROCARE) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Thyrocare Technologies Limited's fair value?
Our blended DCF and relative-valuation model estimates Thyrocare Technologies Limited's fair value at about ₹315.15, versus a current price of ₹566.85 — roughly 44% downside. On that basis the stock looks overvalued by 44%.
Is Thyrocare Technologies Limited financially healthy?
Thyrocare Technologies Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 8/9.
How has Thyrocare Technologies Limited's share price performed?
Thyrocare Technologies Limited is up 44% over the past year and up 3% over three months, and last traded at ₹566.85. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.